Global Companion Diagnostics Market size was valued at USD 4.71 Bn in 2022 and Companion Diagnostics market revenue is expected to reach USD 11.02 Bn by 2029, at a CAGR of 12.9 % over the forecast period.Companion Diagnostics Market Overview
The companion diagnostics for oncology market is witnessing significant growth and transformation driven by advancements in personalized medicine and the development of companion diagnostic tools. This market segment plays a crucial role in the era of precision medicine, where healthcare is increasingly tailored to individual patients based on their unique genetic and molecular profiles. The companion diagnostics market for oncology is characterized by ongoing innovation and development. These diagnostic tools are continually evolving to identify specific biomarkers, genetic mutations, or other molecular characteristics in cancer patients. These advancements are crucial for ensuring that the right patients receive the most suitable targeted therapies, optimizing treatment outcomes. The market is particularly focused on oncology, where companion diagnostics have made significant inroads. The oncology sector benefits immensely from these diagnostic tools, which help oncologists determine the most appropriate treatment strategies, especially in the case of targeted cancer therapies. Collaboration between pharmaceutical companies, diagnostic developers, healthcare institutions, and regulatory agencies is instrumental in the successful development and adoption of companion diagnostics. These partnerships are key drivers for advancing personalized medicine and expanding the market.To know about the Research Methodology :- Request Free Sample Report
Companion Diagnostics Market Dynamics
Increase in number of companion Diagnostic Testing Laboratories to boost the Market growth The growth of companion diagnostic testing laboratories is another driver for the market. Specialized laboratories that conduct companion diagnostic tests are expanding their capabilities and capacity to meet the rising demand, which is expected to boost Companion Diagnostics. These laboratories are equipped with the necessary technology and expertise to perform complex molecular analyses, ensuring accurate and timely results for healthcare providers. The approval of new companion diagnostics by regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), drives market growth. When companion diagnostics receive regulatory approval, it provides confidence in their accuracy and clinical utility. As more companion diagnostics gain approval for use with specific therapies, healthcare providers are more likely to incorporate these tests into their clinical practice, boosting market demand. The increasing development and availability of targeted therapies in various disease areas, including oncology, create a strong driver for companion diagnostics. These therapies are designed to act specifically on the molecular targets identified by companion diagnostics. As more targeted therapies are developed, the demand for companion diagnostics to identify suitable patients for these treatments grows. Regulatory Hurdles to restraint the Companion Diagnostics Market growth The regulatory complexities associated with companion diagnostics pose a significant restraint. Navigating the approval processes required for these tests, which often involve coordination with drug approvals, can be time-consuming and resource-intensive. Stringent regulatory requirements can delay market entry and add to development costs. The development of companion diagnostics requires substantial investments in research, validation studies, and clinical trials. The high development costs deter smaller companies and laboratories from entering the market and limit the availability of companion diagnostics Market for some diseases or conditions. Identifying relevant biomarkers for certain diseases can be a significant constraint. Biomarker discovery is essential for developing effective companion diagnostics, and in some cases, the lack of well-defined biomarkers can limit the development of corresponding tests and therapies. Companion diagnostics often involve the collection and analysis of sensitive patient data. Ensuring data privacy and security while complying with relevant regulations can be a significant restraint, particularly with the increasing focus on data protection and privacy laws. The lack of standardized practices and guidelines for companion diagnostics can hinder their widespread adoption. Standardization is crucial for ensuring consistency, accuracy, and comparability of test results across different laboratories and healthcare settings.Companion Diagnostics Market Segment Analysis
Based on Technology, the market is segmented into PCR, and NGS. PCR Segment is expected to dominate the market over the forecast period. PCR technology is widely utilized in the development of companion diagnostics for oncology, which is expected to boost the Companion Diagnostics Market growth. These diagnostics are specifically designed to identify specific genetic mutations or alterations associated with cancer. They play a critical role in guiding the treatment decisions for cancer patients. PCR allows for the precise and sensitive detection of genetic markers, such as mutations in cancer-associated genes, which is crucial for tailoring personalized treatment plans. PCR is an essential technology for the development of companion diagnostics. As researchers and pharmaceutical companies work to identify biomarkers and genetic variations linked to cancer, PCR provides a reliable and efficient method for detecting these specific genetic changes. This technology is used to validate and refine diagnostic assays, ensuring their accuracy and clinical relevance.Companion Diagnostics Market Regional Insight
North America to hold the largest Companion Diagnostics Market share over the forecast period In 2022, North America, and particularly the United States, dominated the companion diagnostics market. Companion diagnostic tests are considered a significant tool for treatment decisions, especially for many oncology drugs, a classification aligned with the FDA's risk assessment approach. Despite the challenges posed by the COVID-19 pandemic, companion diagnostic tests have gained prominence in the pharmaceutical sector, improving the likelihood of clinical success. In addition to their application in oncology, these tests have experienced high demand for diagnosing COVID-19 cases. The emergence of the novel coronavirus led to intensified research and development efforts in diagnostic testing. In 2022, MiraDx established a testing laboratory in the U.S. dedicated to COVID-19 testing. The facility claims to have accurately conducted more than 9,000 tests.Companion Diagnostics largest service providers in 2022
The rising cancer burden in the United States is expected to be a key driver for market growth. In 2022, the country reported approximately 1.8 million new cancer cases and 606,520 cancer-related deaths, according to a study by MMR. Additionally, favorable reimbursement policies for breast cancer diagnostic solutions in the U.S. are projected to facilitate their adoption. In 2022, the Centers for Medicare and Medicaid Services (CMS) expanded its coverage to include next-generation sequencing as a diagnostic tool for patients with hereditary breast cancer. The growing role of oncology companion diagnostics in the era of next-generation omics is set to propel the market further. For example, in 2022, Guardant Health, Inc. received United States FDA approval for Guardant360 CDx, a companion diagnostic test designed to detect genetic mutations present in cfDNA to assist physicians in identifying patients with non-small cell lung cancer (NSCLC) who would benefit from TAGRISSO treatment. Companion diagnostic tests in the U.S. are categorized as in vitro diagnostic (IVD) class III products, signifying a high-risk classification and therefore the highest level of regulatory oversight. As a result, given the high adoption rates of healthcare expertise and the growing demand for personalized medicine, the United States companion diagnostics market is expected to register significant growth over the forecast period.
Companion Diagnostics Market Competitive Landscape
Companies in the companion diagnostics market continually strive to develop and implement innovative technologies for diagnostic testing, improving accuracy, efficiency, and the range of applications. Strategic collaborations and partnerships are common within the industry. These alliances often involve diagnostic testing laboratories, healthcare providers, and pharmaceutical companies working together to advance companion diagnostics. Companies with a global presence have a competitive advantage. They can leverage their diagnostic tests across multiple markets, serving a broader patient population. To gain a competitive edge, companies focus on expanding their market presence, targeting regions with growing demand for companion diagnostic tests, such as North America.Companion Diagnostics Market Scope: Inquiry Before Buying
Global Companion Diagnostics Market Report Coverage Details Base Year: 2022 Forecast Period: 2023-2029 Historical Data: 2018 to 2022 Market Size in 2022: US$ 4.71 Bn. Forecast Period 2023 to 2029 CAGR: 12.9 % Market Size in 2029: US$ 11.02 Bn. Segments Covered: by Technology PCR NGS by End-Use Hospitals & Clinics Diagnostic Laboratories Research Institutions Pharmaceutical Companies Companion Diagnostics Market, by region
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) North America (United States, Canada and Mexico) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Companion Diagnostics Key Players Include
1. Roche Diagnostics 2. Thermo Fisher Scientific 3. Agilent Technologies 4. Abbott Laboratories 5. Qiagen 6. Myriad Genetics, Inc, 7. Illumina 8. Danaher Corporation 9. Biogenex Laboratories 10. Bio-Rad Laboratories 11. Foundation Medicine 12. Genomic Health 13. NanoString Technologies 14. Guardant Health 15. Invivoscribe Frequently Asked Questions: 1. What is the role of companion diagnostics in personalized medicine? Ans: Companion diagnostics play a crucial role in personalized medicine by identifying specific genetic and molecular markers in patients, allowing healthcare providers to tailor treatment plans based on individual profiles. This approach improves treatment outcomes and minimizes potential side effects. 2. How has the United States contributed to the growth of companion diagnostics in the field of oncology? Ans: The United States, with its prominent role in the companion diagnostics market, has seen significant growth, especially in the field of oncology. The country has witnessed a rising burden of cancer, and favorable reimbursement policies have facilitated the adoption of these diagnostic solutions. Collaboration among pharmaceutical companies, diagnostic developers, healthcare institutions, and regulatory agencies in the U.S. has driven innovation and market expansion. These partnerships have played a pivotal role in advancing personalized medicine and expanding the market. 3. Why is regulatory approval important for companion diagnostics? Ans: Regulatory approval, such as from the U.S. FDA and the European Medicines Agency, instills confidence in the accuracy and clinical utility of companion diagnostics. It leads to wider adoption by healthcare providers, as they trust the approved tests for use with specific therapies. 4. What challenges are associated with regulatory hurdles in companion diagnostics? Ans: Regulatory complexities in companion diagnostics often involve coordination with drug approvals, which can be time-consuming and resource-intensive. Stringent requirements can delay market entry and increase development costs. 5. How does biomarker discovery impact companion diagnostics? Ans: Biomarker discovery is essential for developing effective companion diagnostics. In some cases, the lack of well-defined biomarkers limit the development of corresponding tests and therapies, thus affecting market growth.
1. Companion Diagnostics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Companion Diagnostics Market: Dynamics 2.1. Companion Diagnostics Market Trends by Region 2.1.1. Global Companion Diagnostics Market Trends 2.1.2. North America Companion Diagnostics Market Trends 2.1.3. Europe Companion Diagnostics Market Trends 2.1.4. Asia Pacific Companion Diagnostics Market Trends 2.1.5. Middle East and Africa Companion Diagnostics Market Trends 2.1.6. South America Companion Diagnostics Market Trends 2.2. Companion Diagnostics Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Companion Diagnostics Market Drivers 2.2.1.2. North America Companion Diagnostics Market Restraints 2.2.1.3. North America Companion Diagnostics Market Opportunities 2.2.1.4. North America Companion Diagnostics Market Challenges 2.2.2. Europe 2.2.2.1. Europe Companion Diagnostics Market Drivers 2.2.2.2. Europe Companion Diagnostics Market Restraints 2.2.2.3. Europe Companion Diagnostics Market Opportunities 2.2.2.4. Europe Companion Diagnostics Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Companion Diagnostics Market Drivers 2.2.3.2. Asia Pacific Companion Diagnostics Market Restraints 2.2.3.3. Asia Pacific Companion Diagnostics Market Opportunities 2.2.3.4. Asia Pacific Companion Diagnostics Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Companion Diagnostics Market Drivers 2.2.4.2. Middle East and Africa Companion Diagnostics Market Restraints 2.2.4.3. Middle East and Africa Companion Diagnostics Market Opportunities 2.2.4.4. Middle East and Africa Companion Diagnostics Market Challenges 2.2.5. South America 2.2.5.1. South America Companion Diagnostics Market Drivers 2.2.5.2. South America Companion Diagnostics Market Restraints 2.2.5.3. South America Companion Diagnostics Market Opportunities 2.2.5.4. South America Companion Diagnostics Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Value Chain Analysis 2.6. Regulatory Landscape by Region 2.6.1. Global 2.6.2. North America 2.6.3. Europe 2.6.4. Asia Pacific 2.6.5. Middle East and Africa 2.6.6. South America 2.7. Companion Diagnostics Clinical Trial Analysis for Companion Diagnostics 2.8. Key Opinion Leader Analysis For Companion Diagnostics Industry 2.9. Analysis of Government Schemes and Initiatives For Companion Diagnostics Industry 2.10. The Global Pandemic Impact on Companion Diagnostics Market 2.11. Companion Diagnostics Price Trend Analysis (2021-22) 3. Companion Diagnostics Market: Global Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029) 3.1. Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 3.1.1. PCR 3.1.2. NGS 3.2. Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 3.2.1. Hospitals & Clinics 3.2.2. Diagnostic Laboratories 3.2.3. Research Institutions 3.2.4. Pharmaceutical Companies 3.3. Companion Diagnostics Market Size and Forecast, by Region (2022-2029) 3.3.1. North America 3.3.2. Europe 3.3.3. Asia Pacific 3.3.4. Middle East and Africa 3.3.5. South America 4. North America Companion Diagnostics Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029) 4.1. North America Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 4.1.1. PCR 4.1.2. NGS 4.2. North America Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 4.2.1. Hospitals & Clinics 4.2.2. Diagnostic Laboratories 4.2.3. Research Institutions 4.2.4. Pharmaceutical Companies 4.3. North America Companion Diagnostics Market Size and Forecast, by Country (2022-2029) 4.3.1. United States 4.3.1.1. United States Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 4.3.1.1.1. PCR 4.3.1.1.2. NGS 4.3.1.2. United States Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 4.3.1.2.1. Hospitals & Clinics 4.3.1.2.2. Diagnostic Laboratories 4.3.1.2.3. Research Institutions 4.3.1.2.4. Pharmaceutical Companies 4.3.2. Canada 4.3.2.1. Canada Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 4.3.2.1.1. PCR 4.3.2.1.2. NGS 4.3.2.2. Canada Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 4.3.2.2.1. Hospitals & Clinics 4.3.2.2.2. Diagnostic Laboratories 4.3.2.2.3. Research Institutions 4.3.2.2.4. Pharmaceutical Companies 4.3.3. Mexico 4.3.3.1. Mexico Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 4.3.3.1.1. PCR 4.3.3.1.2. NGS 4.3.3.2. Mexico Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 4.3.3.2.1. Hospitals & Clinics 4.3.3.2.2. Diagnostic Laboratories 4.3.3.2.3. Research Institutions 4.3.3.2.4. Pharmaceutical Companies 5. Europe Companion Diagnostics Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029) 5.1. Europe Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.2. Europe Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3. Europe Companion Diagnostics Market Size and Forecast, by Country (2022-2029) 5.3.1. United Kingdom 5.3.1.1. United Kingdom Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.1.2. United Kingdom Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.2. France 5.3.2.1. France Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.2.2. France Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.3. Germany 5.3.3.1. Germany Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.3.2. Germany Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.4. Italy 5.3.4.1. Italy Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.4.2. Italy Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.5. Spain 5.3.5.1. Spain Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.5.2. Spain Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.6. Sweden 5.3.6.1. Sweden Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.6.2. Sweden Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.7. Austria 5.3.7.1. Austria Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.7.2. Austria Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 5.3.8. Rest of Europe 5.3.8.1. Rest of Europe Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 5.3.8.2. Rest of Europe Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6. Asia Pacific Companion Diagnostics Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029) 6.1. Asia Pacific Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.2. Asia Pacific Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3. Asia Pacific Companion Diagnostics Market Size and Forecast, by Country (2022-2029) 6.3.1. China 6.3.1.1. China Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.1.2. China Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.2. S Korea 6.3.2.1. S Korea Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.2.2. S Korea Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.3. Japan 6.3.3.1. Japan Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.3.2. Japan Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.4. India 6.3.4.1. India Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.4.2. India Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.5. Australia 6.3.5.1. Australia Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.5.2. Australia Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.6. Indonesia 6.3.6.1. Indonesia Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.6.2. Indonesia Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.7. Malaysia 6.3.7.1. Malaysia Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.7.2. Malaysia Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.8. Vietnam 6.3.8.1. Vietnam Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.8.2. Vietnam Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.9. Taiwan 6.3.9.1. Taiwan Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.9.2. Taiwan Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.10. Rest of Asia Pacific 6.3.10.1. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 6.3.10.2. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 6.3.10.3. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, by Indication (2022-2029) 6.3.10.4. Rest of Asia Pacific Companion Diagnostics Market Size and Forecast, by End User(2022-2029) 7. Middle East and Africa Companion Diagnostics Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029 7.1. Middle East and Africa Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 7.2. Middle East and Africa Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 7.3. Middle East and Africa Companion Diagnostics Market Size and Forecast, by Country (2022-2029) 7.3.1. South Africa 7.3.1.1. South Africa Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 7.3.1.2. South Africa Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 7.3.2. GCC 7.3.2.1. GCC Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 7.3.2.2. GCC Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 7.3.3. Nigeria 7.3.3.1. Nigeria Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 7.3.3.2. Nigeria Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 7.3.4. Rest of ME&A 7.3.4.1. Rest of ME&A Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 7.3.4.2. Rest of ME&A Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 8. South America Companion Diagnostics Market Size and Forecast by Segmentation for Demand and Supply Side (by Value in USD Million) (2022-2029 8.1. South America Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 8.2. South America Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 8.3. South America Companion Diagnostics Market Size and Forecast, by Country (2022-2029) 8.3.1. Brazil 8.3.1.1. Brazil Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 8.3.1.2. Brazil Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 8.3.2. Argentina 8.3.2.1. Argentina Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 8.3.2.2. Argentina Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 8.3.3. Rest Of South America 8.3.3.1. Rest Of South America Companion Diagnostics Market Size and Forecast, by Technology (2022-2029) 8.3.3.2. Rest Of South America Companion Diagnostics Market Size and Forecast, by End User (2022-2029) 9. Global Companion Diagnostics Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Product Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Market Analysis by Organized Players vs. Unorganized Players 9.4.1. Organized Players 9.4.2. Unorganized Players 9.5. Leading Companion Diagnostics Market Companies, by market capitalization 9.6. Market Structure 9.6.1. Market Leaders 9.6.2. Market Followers 9.6.3. Emerging Players 9.7. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Roche Diagnostics 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Thermo Fisher Scientific 10.3. Agilent Technologies 10.4. Abbott Laboratories 10.5. Qiagen 10.6. Myriad Genetics 10.7. Illumina 10.8. Danaher Corporation 10.9. Biogenex Laboratories 10.10. Bio-Rad Laboratories 10.11. Foundation Medicine 10.12. Genomic Health 10.13. NanoString Technologies 10.14. Guardant Health 10.15. Invivoscribe 11. Key Findings 12. Industry Recommendations 13. Companion Diagnostics Market: Research Methodology 14. Terms and Glossary